Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page 7 p0 J6 Z0 ~, ]5 |6 Z2 }3 B$ f
: r0 u. ^, ~ G! ^
; i0 f9 O. T. e8 uSub-category:
+ C9 n4 J0 S) P* P c! u5 }Molecular Targets
7 z& M. b, w' C8 \
" h# z' W- b" R
b; F: p4 t# n0 }+ P3 |3 GCategory:# w$ R" L' g( b: @
Tumor Biology
; p/ n, z8 C0 d/ _6 `' L7 m. V6 {. s: _% [( _
! p) p4 T# `. X3 q4 D. T4 jMeeting:' ?. U7 D3 L, Z) t6 R! f
2011 ASCO Annual Meeting
/ M4 h" [" W! N) k, P/ r
% O! r0 Y( `& N7 d; J& e' t- l6 Z% u- Y4 h, I8 c8 v2 R! N' T/ p7 u
Session Type and Session Title:0 `% F k& [( k9 }
Poster Discussion Session, Tumor Biology " Y# O6 H% i2 u, T4 O
- U! M0 g5 G1 T8 s W1 F% Z# k
/ y; U* N+ R" s# L8 FAbstract No:
! |# U# J( K/ Y6 U8 I# H9 s10517
; {& E' m/ O0 [4 e0 Y
. d# m: g! Z+ g }0 r4 ]& J5 X
4 y. J& V' U: K1 d: ]9 C' P0 ICitation:# [+ k! h! c9 I4 [+ a* ]* u$ J9 }. L
J Clin Oncol 29: 2011 (suppl; abstr 10517)
b8 ^( ]3 i2 \, r
3 a# B5 x8 M' k `% I
; A" B% e. k7 Z' Q4 ~$ zAuthor(s):
& |- k1 e" s' S @J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
1 K2 j) R+ k2 `7 B. {, W5 {4 c; e) L# \7 D5 T' B/ z; D
1 k2 a9 E1 m" }' @1 y C
- o! R% W0 C8 G6 y( _Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
2 f. U+ {3 T6 O( e0 x v
: e3 ?% q0 u+ Z8 v z/ `8 r+ gAbstract Disclosures
% }5 a, s4 Z( S" }% y+ g% @" [4 Q( B' C2 g4 z# r0 O/ V
Abstract:" V. L: ]7 ]- }3 D) }) {2 E; G
# x' O# v) C0 p! v, o0 J
b2 X- [& P1 x' `/ S9 |: t$ o
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.; X9 X$ A5 Q& u& e
0 n6 S/ Z/ @' j- O5 k8 q; Q4 O4 a 0 l0 r7 e% ?7 b( J
|